Five blood biomarkers spanning inflammation, coagulation, oxidation, and cell death pathways — including the neuropeptide substance P — are linked to mortality risk after traumatic brain injury.
5 biomarkers identifiedSubstance P, sCD40L, TIMP-1, MDA, and fragmented CK-18 each reflect a different secondary injury pathway and correlate with TBI mortality
What the researchers found
Five circulating biomarkers — substance P (a neuropeptide), soluble CD40 ligand, TIMP-1, malondialdehyde, and fragmented cytokeratin-18 — have been identified as prognostic indicators of mortality in traumatic brain injury patients. Each biomarker reflects a different pathway of secondary brain injury: substance P indicates neuroinflammation, sCD40L reflects coagulation and inflammation, TIMP-1 relates to neuroinflammatory matrix remodeling, MDA marks oxidative damage, and CK-18 fragmented signals apoptotic cell death.
Substance P, a tachykinin family neuropeptide synthesized in the central and peripheral nervous system, exerts proinflammatory effects through binding to neurokinin-1 receptors, making it a particularly relevant peptide biomarker in brain injury.
Why it matters
Traumatic brain injury is a leading cause of death and disability, and much of the damage occurs in the hours and days after impact through secondary injury pathways. Blood-based biomarkers that predict which patients are at highest risk of dying could help clinicians make faster, more targeted treatment decisions and may point toward new therapeutic targets.
The numbers in context
5 novel biomarkers · 4 pathways (inflammation, coagulation, oxidation, apoptosis)
How the study worked
This is a narrative review summarizing recent studies that identified circulating blood biomarkers associated with mortality in traumatic brain injury patients. The review covers biomarkers across four key secondary injury pathways.
Who was studied
Patients with traumatic brain injury (TBI)
What this study cannot tell us
As a narrative review, this paper does not present new experimental data or perform a systematic analysis of the evidence. The specific study designs, sample sizes, and statistical strength behind each biomarker association are not detailed in the abstract. The clinical utility of these biomarkers in routine practice remains to be validated.
How to read the evidence
This is a narrative review summarizing associations between biomarkers and TBI mortality from multiple studies. While the associations are promising, the review does not provide pooled statistical analysis or assess study quality systematically.
When this study was published
Published in 2015, this review covers biomarker research from that era. Subsequent studies may have further validated or refined these prognostic markers.
The bigger picture
Prognostic biomarkers are increasingly important in critical care medicine. For traumatic brain injury, having reliable blood tests that predict outcomes could transform how clinicians triage and treat patients. The inclusion of substance P — a neuropeptide — highlights the role of peptide signaling in brain injury and recovery.
Questions still open
- Can these biomarkers be combined into a single prognostic panel that outperforms any individual marker?
- Could blocking substance P's neurokinin-1 receptor reduce secondary brain injury and improve TBI survival?
- At what time points after injury are these biomarkers most predictive of outcomes?
Common questions
What is substance P and why is it relevant to brain injury?
Could these biomarkers lead to new treatments for TBI?
Read the original research
New Prognostic Biomarkers in Patients With Traumatic Brain Injury.
Archives of trauma research, 4(4), e30165
Citation
Lorente, Leonardo. (2015). New Prognostic Biomarkers in Patients With Traumatic Brain Injury.. Archives of trauma research, 4(4), e30165. https://doi.org/10.5812/atr.30165